

Ezrin(Phospho-Tyr353) Antibody

Catalog No: #11063

Package Size: #11063-1 50ul #11063-2 100ul

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com

Description

Product Name	Ezrin(Phospho-Tyr353) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Applications	WB IHC
Species Reactivity	Human
Specificity	The antibody detects endogenous level of Ezrin only when phosphorylated at tyrosine 353.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of tyrosine 353 (Q-D-Y(p)-E-E) derived from Human EZRIN.
Conjugates	Unconjugated
Target Name	Ezrin
Modification	Phospho
Other Names	Cytovillin; EZRI; VIL2; Villin 2; p81
Accession No.	Swiss-Prot: P15311NCBI Protein: NP_001104547.1
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.


Application Details

Predicted MW: 81kd


Western blotting: 1:500~1:1000

Immunohistochemistry: 1:50~1:100

Images



Western blot analysis of extracts from 293 cells untreated or treated with EGF using Ezrin(Phospho-Tyr353) Antibody #11063.



Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Ezrin(Phospho-Tyr353) Antibody #11063(left) or the same antibody preincubated with blocking peptide(right).

Background

Probably involved in connections of major cytoskeletal structures to the plasma membrane. In epithelial cells, required for the formation of microvilli and membrane ruffles on the apical pole. Along with PLEKHG6, required for normal macropinocytosis.

Zhao H, et al. (2004) Proc Natl Acad Sci U S A 101 (25): 9485-9490.

Wang Q, et al. (2003) J Biol Chem 278(48): 47731-47743.

Gautreau A, et al. (1999) Proc Natl Acad Sci U S A 96(13): 7300-7305.

Crepaldi T, et al. (1997) J Cell Biol 138(2): 423-34.

Published Papers

Yazhou Cui, Tianliang Li, Denglu Zhang et al., Expression of Ezrin and Phosphorylated Ezrin (pEzrin) in Pancreatic Ductal Adenocarcinoma., Cancer Investigation, 28(3) 242-247(2010)

[PMID:20158339](#)

Yasunori Oda MD, Shinichi Aishima PhD, Katsuya Morimatsu PhD et al., Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas., Human Pathology, 44(8):1487-1498 (2012)

[PMID:23465281](#)

et al., Expression of Ezrin and Phosphorylated Ezrin (pEzrin) in Pancreatic Ductal Adenocarcinoma. In Cancer Invest on 2010 Mar by Cui Y1, Li T, et al..PMID:20158339, , (2010)

[PMID:20158339](#)

et al., Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal

carcinoma of the pancreas. In Hum Pathol on 2013 Aug by Yasunori Oda, Shinichi Aishima, et al..PMID: 23465281, , (2013)

[PMID:23465281](#)

et al., Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer. In BMC Cancer on 2014 Mar 15 by Tiefeng Jin, Jingchun Jin et al ..PMID: 24629131, , (2014)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.